Asynchronous Teledermatology for Non-Scarring Alopecia: A Retrospective Study.
Study Design
- Tipo di studio
- retrospective cohort study
- Dimensione del campione
- 321
- Intervento
- Asynchronous Teledermatology for Non-Scarring Alopecia: A Retrospective Study. Minoxidil (OTC) and clobetasol for mild cases; prescription medications for moderate-severe. Specifi
- Comparatore
- Placebo
- Direzione dell'effetto
- Positive
- Rischio di bias
- High
Abstract
BACKGROUND: Non-scarring alopecia, including androgenetic alopecia (AGA), alopecia areata (AA), telogen effluvium (TE), and traction alopecia (TA), significantly impacts psychosocial well-being. Access to specialized dermatologic care for these conditions is often limited, particularly in underserved populations. Asynchronous teledermatology has emerged as a potential solution to extend care to these groups. OBJECTIVE: To evaluate the diagnostic utility and treatment patterns of asynchronous teledermatology for non-scarring alopecia and examine its role in improving care access across diverse populations within the University of Pittsburgh Medical Center (UPMC) network. METHODS: A retrospective study of 321 asynchronous teledermatology cases of non-scarring alopecia from 2022 to 2023 was conducted using the UPMC medical record system. Diagnosist, treatment type, and demographic data were analyzed. Longitudinal outcomes and adherence data were not consistently available. RESULTS: AA was the most common diagnosis (59.5%), followed by AGA (26.5%), TE (7.5%), and TA (5.0%). A definitive diagnosis was made remotely in 91.3% of cases; only 8.7% required in-person follow-up. Treatment included over-the-counter therapies such as minoxidil and clobetasol, with prescription medications used for moderate to severe cases. Racial demographics reflected high engagement from Black (22.7%) and Asian (12.9%) patients, with 41.7% of patients residing outside Pittsburgh. CONCLUSION: Asynchronous teledermatology is an effective tool for diagnosing and managing non-scarring alopecia, facilitating timely intervention and improving access to dermatologic care. Future studies should access patient satisfaction, long-term outcomes, and implementation strategies to further expand equitable teledermatology access.
Full Text
Tables
Table 1.
| Patients in 2022 ( | Patients in 2023 ( | |
|---|---|---|
| Primary hair loss pattern | ||
| Alopecia/areata | 114 | 77 |
| Traction alopecia | 5 | 11 |
| AGA | 22 | 63 |
| TE | 12 | 12 |
| Other | 1 | 5 |
| Appointment Setting | ||
| e-Derm | 146 | 157 |
| e-Consult: Outpatient | 7 | 10 |
| Inpatient | 1 | 0 |
Table 2.
| Characteristics | Patients in 2022 ( | Patients in 2023 ( |
|---|---|---|
| Demographics | ||
| Age, mean (SD) | 39.2 ± (14.2) | 37.3 ± (13.2) |
| Gender | ||
| Male | 40.26 | 45.51 |
| Female | 59.74 | 54.49 |
| Race/ethnicity | ||
| NH White | 53.25 | 60.48 |
| NH Black | 22.72 | 22.75 |
| NH Asian | 15.58 | 10.18 |
| Hispanic | 1.23 | 0.599 |
| Other/unreported | 4.54 | 5.39 |
Table 3.
| Alopecia subtype | OTC treatments (%) | Prescription treatments (%) | Education materials (%) | Other recommendations (%) |
|---|---|---|---|---|
| Alopecia/Areata | 86 (45.0%) | 58 (30.4%) | 173 (90.6%) | 51 (26.7%) |
| Androgenetic Alopecia (AGA) | 69 (81.2%) | 31 (36.5%) | 81 (95.3%) | 7 (8.2%) |
| Telogen Effluvium (TE) | 13 (54.2%) | 2 (8.3%) | 24 (100%) | 7 (29.2%) |
| Traction Alopecia (TA) | 9 (56.3%) | 3 (18.8%) | 15 (93.8%) | 3 (18.8%) |
| Other | 0 (0%) | 4 (80%) | 3 (60%) | 1 (20%) |
References
- Psychological profile and quality of life of patients with alopecia areata Skin Appendage Disord, 2019
- Alopecia areata Nat Rev Dis Primers, 2017
- Teledermatology as a tool to improve access to care for medically underserved populations: A retrospective descriptive study J Am Acad Dermatol, 2016
- Measurement of Health-Related Quality of Life in Patients with Hair Loss JAMA Dermatol
- Teledermatology in alopecia: A systematic review JAAD Int, 2024
- Teledermatology: An evidence map of systematic reviews Syst Rev, 2024
- Alopecia areata: An update on etiopathogenesis, diagnosis, and management Clin Rev Allergy Immunol, 2021
- Diagnostic reliability in teledermatology: A systematic review and a meta-analysis BMJ Open, 2023
- Barriers and facilitators to skin cancer prevention among Hispanics: A qualitative study BMC Public Health, 2024
- British association of dermatologists’ guidelines for the management of alopecia areata 2012 Br J Dermatol, 2012
Used In Evidence Reviews
Similar Papers
Annual review of nutrition · 2004
Secular trends in dietary intake in the United States.
Journal of the American Academy of Dermatology · 2002
A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.
Journal of the American Academy of Dermatology · 2017
The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis.
Current problems in dermatology · 2015
Alopecia areata.
Drug design, development and therapy · 2019
Minoxidil and its use in hair disorders: a review.
Journal of cosmetic dermatology · 2021